Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

被引：7

作者：

Li, Chenggong ^{[1
]}

Wang, Xindi ^{[1
]}

Wu, Zhuolin ^{[1
]}

Luo, Wenjing ^{[1
]}

Zhang, Yinqiang ^{[1
]}

Kang, Yun ^{[1
]}

Xu, Jia ^{[1
]}

Huang, Zhongpei ^{[1
]}

Du, Mengyi ^{[1
]}

Tang, Lu ^{[1
]}

Wu, Jianghua ^{[1
]}

Liao, Danying ^{[1
]}

Kou, Haiming ^{[1
]}

Lu, Cong ^{[1
]}

Jiang, Huiwen ^{[1
]}

Wei, Qiuzhe ^{[1
]}

Ke, Sha ^{[1
]}

Zheng, Jing'e ^{[1
]}

Xiong, Wei ^{[2
]}

Deng, Jun ^{[1
]}

Hu, Yu ^{[1
]}

Mei, Heng ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China

[2] Wuhan Sian Med Technol Co Ltd, Wuhan, Peoples R China

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170686

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4573 / 4574

页数：2

共 50 条

[1] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Li, Chenggong
Xu, Jia
Luo, Wenjing
Liao, Danying
Xie, Wei
Wei, Qiuzhe
Zhang, Yinqiang
Wang, Xindi
Wu, Zhuolin
Kang, Yun
Zheng, Jin'e
Xiong, Wei
Deng, Jun
Hu, Yu
Mei, Heng
LEUKEMIA, 2024, 38 (01) : 149 - 159
[2] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Chenggong Li
Jia Xu
Wenjing Luo
Danying Liao
Wei Xie
Qiuzhe Wei
Yinqiang Zhang
Xindi Wang
Zhuolin Wu
Yun Kang
Jin’e Zheng
Wei Xiong
Jun Deng
Yu Hu
Heng Mei
Leukemia, 2024, 38 : 149 - 159
[3] Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
Golubovskaya, Vita
Zhou, Hua
Li, Feng
Berahovich, Robert
Sun, Jinying
Valentine, Michael
Xu, Shirley
Harto, Hizkia
Sienkiewicz, John
Huang, Yanwei
Wu, Lijun
BIOMEDICINES, 2021, 9 (10)
[4] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Zhang, Hua
Gao, Lei
Liu, Li
Wang, Jishi
Wang, Sanbin
Gao, Li
Zhang, Cheng
Liu, Yao
Kong, Peiyan
Liu, Jia
He, Jiaping
Han, Yu
Shi, Hua
He, Yan
Ye, Xun
Zhao, Yi
Cao, Wei
Shen, Lianjun
Zhang, Xi
BLOOD, 2019, 134
[5] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang
Haisen Yin
Xinying Zhao
Dan Jin
Yan Liang
Tao Xiong
Lu Li
Wen Tang
Jiangzhao Zhang
Min Liu
Zhuojun Yu
Huimin Liu
Sibin Zang
Zhiping Huang
Journal of Experimental & Clinical Cancer Research, 41
[6] High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Tang, Yuanyan
Yin, Haisen
Zhao, Xinying
Jin, Dan
Liang, Yan
Xiong, Tao
Li, Lu
Tang, Wen
Zhang, Jiangzhao
Liu, Min
Yu, Zhuojun
Liu, Huimin
Zang, Sibin
Huang, Zhiping
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[7] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei
Chenggong Li
Huiwen Jiang
Xinying Zhao
Zhiping Huang
Dan Jin
Tao Guo
Haiming Kou
Lin Liu
Lu Tang
Ping Yin
Zhihui Wang
Lisha Ai
Sha Ke
Yimeng Xia
Jun Deng
Lei Chen
Li Cai
Chunyan Sun
Linghui Xia
Gaoquan Hua
Yu Hu
Journal of Hematology & Oncology, 14
[8] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, Heng
Li, Chenggong
Jiang, Huiwen
Zhao, Xinying
Huang, Zhiping
Jin, Dan
Guo, Tao
Kou, Haiming
Liu, Lin
Tang, Lu
Yin, Ping
Wang, Zhihui
Ai, Lisha
Ke, Sha
Xia, Yimeng
Deng, Jun
Chen, Lei
Cai, Li
Sun, Chunyan
Xia, Linghui
Hua, Gaoquan
Hu, Yu
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[9] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Zah, Eugenia
Nam, Eunwoo
Bhuvan, Vinya
Tran, Uyen
Ji, Brenda Y.
Gosliner, Stanley B.
Wang, Xiuli
Brown, Christine E.
Chen, Yvonne Y.
NATURE COMMUNICATIONS, 2020, 11 (01)
[10] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah
Eunwoo Nam
Vinya Bhuvan
Uyen Tran
Brenda Y. Ji
Stanley B. Gosliner
Xiuli Wang
Christine E. Brown
Yvonne Y. Chen
Nature Communications, 11

← 1 2 3 4 5 →